These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 22116466

  • 1. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
    Yuan H, Wang Z, Zhang H, Roth M, Bhatia R, Chen WY.
    Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Blood; 2008 Apr 15; 111(8):4355-64. PubMed ID: 18268096
    [Abstract] [Full Text] [Related]

  • 3. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
    Donato NJ, Fang D, Sun H, Giannola D, Peterson LF, Talpaz M.
    Biochem Pharmacol; 2010 Mar 01; 79(5):688-97. PubMed ID: 19874801
    [Abstract] [Full Text] [Related]

  • 4. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
    Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS.
    J Cell Mol Med; 2011 Oct 01; 15(10):2057-70. PubMed ID: 21091633
    [Abstract] [Full Text] [Related]

  • 5. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J, Shen P, Zhang G, Wu X, Zhang X.
    Biomed Pharmacother; 2013 Mar 01; 67(2):157-63. PubMed ID: 23201011
    [Abstract] [Full Text] [Related]

  • 6. ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
    Wang Z, Liu Z, Wu X, Chu S, Wang J, Yuan H, Roth M, Yuan YC, Bhatia R, Chen W.
    PLoS Genet; 2014 Jun 01; 10(6):e1004414. PubMed ID: 24967705
    [Abstract] [Full Text] [Related]

  • 7. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
    Balabanov S, Gontarewicz A, Keller G, Raddrizzani L, Braig M, Bosotti R, Moll J, Jost E, Barett C, Rohe I, Bokemeyer C, Holyoake TL, Brümmendorf TH.
    PLoS One; 2011 Apr 26; 6(4):e19164. PubMed ID: 21541334
    [Abstract] [Full Text] [Related]

  • 8. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
    Härtel N, Klag T, Hanfstein B, Mueller MC, Schenk T, Erben P, Hochhaus A, La Rosée P.
    J Cancer Res Clin Oncol; 2012 Feb 26; 138(2):203-12. PubMed ID: 22089930
    [Abstract] [Full Text] [Related]

  • 9. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.
    Clin Cancer Res; 2014 Jan 01; 20(1):151-63. PubMed ID: 24334603
    [Abstract] [Full Text] [Related]

  • 10. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.
    Acta Pharmacol Sin; 2014 Mar 01; 35(3):401-9. PubMed ID: 24487968
    [Abstract] [Full Text] [Related]

  • 11. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng JX.
    PLoS One; 2017 Mar 01; 12(7):e0179558. PubMed ID: 28719608
    [Abstract] [Full Text] [Related]

  • 12. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
    Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P.
    Oncotarget; 2012 Dec 01; 3(12):1557-65. PubMed ID: 23238683
    [Abstract] [Full Text] [Related]

  • 13. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 14. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G, Toto C, Palamà I, De Leo S, de Luca E, De Matteis S, Dini L, Passerini CG, Di Renzo N, Maffia M, Coluccia AM.
    Blood; 2012 Mar 08; 119(10):2335-45. PubMed ID: 22262776
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
    Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP.
    Leuk Lymphoma; 2011 Nov 08; 52(11):2139-47. PubMed ID: 21718141
    [Abstract] [Full Text] [Related]

  • 16. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P.
    Cancer Res; 2010 Feb 15; 70(4):1513-23. PubMed ID: 20145140
    [Abstract] [Full Text] [Related]

  • 17. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y, Nakamura S, Okinaka K, Hirano I, Ono T, Shigeno K, Shinjo K, Ohnishi K.
    Leuk Res; 2008 Jun 15; 32(6):962-71. PubMed ID: 18190961
    [Abstract] [Full Text] [Related]

  • 18. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
    Yuan H, Wang Z, Gao C, Chen W, Huang Q, Yee JK, Bhatia R, Chen W.
    J Biol Chem; 2010 Feb 12; 285(7):5085-96. PubMed ID: 20007699
    [Abstract] [Full Text] [Related]

  • 19. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
    Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Köcher T, Superti-Furga G.
    Blood; 2007 Dec 01; 110(12):4055-63. PubMed ID: 17720881
    [Abstract] [Full Text] [Related]

  • 20. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J.
    Mol Cancer; 2010 May 19; 9():112. PubMed ID: 20482842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.